LONGEVERON INC.

- USD (-)

- 15 min delayed data - NASDAQ Stocks

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	LGVN
ISIN:

LONGEVERON INC. overview

> News GlobeNewsWire published a news.

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common...

Thank you Chart

> News GlobeNewsWire published a news.

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its...

Thank you Chart

> News GlobeNewsWire published a news.

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC) • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results. CLEAR-MIND is a Phase 2a randomized clinical trial evaluating Lomecel-B TM in mild Alzheimer’s Disease. In addition to the clinical study results, the Company has been accepted for a poster presentation...

Thank you Chart

> Analyses

Londinia AI has published a new analysis for nfkhamis.

0
72780
15109
0

LONGEVERON INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

The bearish trend is currently very strong for LONGEVERON INC.. As long as the price remains below the resistance at 2.03 USD, you could try to take advantage of the bearish rally. The first bearish…

Thank you Reply Chart

> News GlobeNewsWire published a news.

Longeveron Announces Closing of $5.2 Million Public Offering • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced public offering of up to 2,234,043 shares of the Company’s Class A common stock (or pre-funded warrants...

Thank you Chart

> Analyses

Londinia AI has published a new analysis for nfkhamis.

0
72780
15109
0

LONGEVERON INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

All elements being clearly bearish, it would be possible for traders to trade only short positions (for sale) on LONGEVERON INC. as long as the price remains well below 2.27 USD. The sellers' bearish…

Thank you Reply Chart

> News GlobeNewsWire published a news.

Longeveron Announces Pricing of $5.25 Million Public Offering • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the pricing of a public offering of 2,234,043 shares of the Company’s Class A common stock (or pre-funded warrants in lieu thereof) and warrants to...

Thank you Chart

> News GlobeNewsWire published a news.

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals • • GlobeNewsWire • Stocks • More LONGEVERON INC. news...

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Shareholders, I am delighted to mark my first anniversary as CEO of Longeveron this month. It has been an extraordinary journey thus far, and I am immensely grateful for the opportunity to lead such a pioneering organization...

Thank you Chart

Load more content